{
  "catalogId": "14924137-7a27-43f6-905d-33e2bac48b23",
  "name": "RYDAPT ® 25 MG",
  "status": "draft",
  "category": "prescription",
  "registrationValidity": "valid",
  "registrationNumber": "160 65 35320 00",
  "treatmentDescriptions": "Acute myeloid leukaemia (AML) :Rydapt is indicated in combination with standard induction and consolidation chemotherapy followed by single-agent maintenance therapy for adults with newly diagnosed acute myeloid leukaemia (AML) who have an FLT3 mutation.Advanced systemic mastocytosis (advanced SM) :Rydapt is indicated for the treatment of adult patients with advanced systemic mastocytosis (advanced SM).",
  "termsOfIssue": "Prescription required",
  "form": "capsule, soft",
  "route": "per os",
  "site": "",
  "method": "",
  "administrationNotes": "",
  "ingredients": "MIDOSTAURIN",
  "codes": {
    "atc5": {
      "system": "WHO ATC Classification",
      "code": "L01XE40",
      "name": "MIDOSTAURIN"
    }
  },
  "contraindications": "",
  "sideEffect": "",
  "warnings": "תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת",
  "alternativeMedications": [],
  "packaging": [
    {
      "name": "RYDAPT 25 MG 112 CAPSULES",
      "manufacturer": {
        "name": "נוברטיס פארמה",
        "countryOfOrigin": "IL"
      },
      "strength": {
        "value": 0,
        "unit": ""
      },
      "quantity": {
        "value": 112.0,
        "unit": "units"
      },
      "packagingDescription": "BLISTER PACK PA/ALUMINIUM/PVC",
      "shelfLife": "36",
      "storageConditions": "",
      "codes": {
        "moh": "8106",
        "yarpa": "10113",
        "pharmasoft": "18585"
      },
      "manufacturersAdministrationRecommendation": "",
      "pricing": {
        "currency": "ILS",
        "maxWholesalePrice": 45691.70224,
        "retailMargin": 10.0,
        "maxRetailPrice": 50260.87246,
        "maxPriceWithVAT": 59307.82687
      }
    }
  ],
  "metadata": {
    "version": "1.4",
    "lastUpdated": "2025-08-01T12:18:43.023469"
  }
}